anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, homeopathy. SUBSTANCE: invention relates to development of complex homeopathic medicinal agents used for treatment of patients with polyarthritis, arthrosis and rheumatism. Proposed agent has Rhus toxicidendron C3, Colchicum automnale C3, Lithium carbonicum C3, Hepar sulfuris C6, Lycopodium clavatum C3, Calcarea fluorica C6 and all components are taken in equal parts. Agent can be made as sugar granules. Treatment with proposed agent results to improvement of state and health of patients, remission of disease and then its regression, joint pains are weakened, joint contracture is diminished slowly. Except for, cartilage and osseous tissues are raised, damaged joints are recovered and their deformation is disappeared in patients with less of 3 years of disease. EFFECT: enhanced effectiveness of agent. 2 cl
Hidradenitis suppurativa (HS) is a chronic disease of the folliculopilosebaceous unit, often found in intertriginous areas of the body. The pain and impairment of HS leads patients to report a decreased quality of life, even in comparison to other debilitating cutaneous disease states. Pharmalogic management of HS can vary from topical antibiotics or intralesional corticosteroids for mild cases to immunosuppressants and biologic agents in refractory cases. Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration. It is our hypothesis that gentian violet will help minimize skin trauma in sites of active HS to promote improved wound healing and quality of life.
The disclosed systems relate to generating brain data visualizations based on federated analysis of brain data. In exemplary embodiments, the brain data visualizations are generated using a system comprising a framework. The framework may include a first computing platform that comprises one or more servers. The framework may also include a first application for communicating via a communication network with a second computing platform that is different from the first computing platform. The second computing platform may comprise a database that stores protected medical data including a plurality of data elements that are directly inaccessible individually or directly inaccessible in aggregate by a user of the first computing platform. In one embodiment, the one or more servers of the first computing platform comprise memory storing instructions that are executable by one or more computer processors of the first computing platform to execute the various processing stages outlined in this disclosure.
The invention starts from a healing plaster which is provided on one side with an adhesive adhering to the human skin. The invention is based on the object of designing this plaster in such a way that it can be used for reflex zone treatment of the feet without having to employ any manual therapy. This is achieved, according to the invention, by a healing plaster which contains a preferably hyperaemising active substance and possesses the shape of at least one reflex zone segment of the surface of the human foot. This plaster can be punched out and contain capsaicin and fruct. capsici frut. BPC as active substances.
PURPOSE: To obtain a sustained release spongy material composed of hyaluronic acid or its derivative and useful for microscopic surgery of otological surgery, aur-neurological surgery and dental oral surgery. CONSTITUTION: This sustained release spongy material is composed of hyaluronic acid or its derivative (especially preferably ethyl hyaluronate). The spongy material is obtained by freeze-drying an aqueous solution of hyaluronic acid or its derivative having 1-40mg/ml concentration. An aqueous solution containing hyaluronic acid or its derivative is used after filtering with a aseptized membrane having 0.2 micrometer hole. Further preferably, the aqueous solution is frozen at 0 to -90 deg.C at first and then, heated to -90 to 60 deg.C plate temperature. A freezing process is preferably carried out at a temperature-decreasing rate of 1 deg.C/20sec to 1 deg.C/3hr and sublimation process is preferably carried out at a temperature-raising rate of 1 deg.C/20sec to 1 deg.C/8hr.
OBJECTIVES: To investigate associations between the rectoanal inhibitory reflex (RAIR), type of congenital anorectal malformations (ARMs), type of operation that patients with ARM had undergone, and objectively measured fecal incontinence and defecation problems.
METHODS: We retrospectively included 69 pediatric patients with ARM. All underwent anorectal function tests at the University Medical Center of Groningen during the last 10 years. We assessed anorectal physiology using the Rome IV criteria and anorectal function tests.
RESULTS: We found the reflex in 67% of patients and all types of ARMs. All patients who had not been operated on, and those who had undergone less extensive surgery possessed the reflex. In contrast, patients who underwent posterior sagittal anorectoplasty, 44% possessed it. We found no difference between mean rectal volumes in patients with and without the reflex (251  vs. 325 mL, respectively, p = 0.266). We found that over time, patients without the reflex seemed to develop significantly higher rectal volumes than patients who had it. We did not find a significant difference between the reflex and fecal incontinence; however, it seems that the absence of the reflex, resting anal sphincter pressure, and fecal incontinence are related.
CONCLUSION: The RAIR seems present in patients with ARM irrespective of their malformation type. Corrective surgery, however, may impair this reflex. Seemingly, its absence results in constipation with enlarged rectal volumes and fecal incontinence. Every effort should be made to preserve this reflex during surgery and to use extensive surgical procedures as sparingly as possible.
The present disclosure relates to methods and agents for enhancing the effect of T cells engineered to express chimeric antigen receptors (CARs). These methods and agents are, in particular, useful for the treatment of diseases characterized by diseased cells expressing an antigen the CAR is directed to.Specifically, the present disclosure relates to methods comprising providing to a subject T cells genetically modified to express a chimeric antigen receptor (CAR) and administering to the subject IL2 or a polynucleotide encoding IL2. The methods of the disclosure may comprise administering IL2 or a polynucleotide encoding IL2 and a further cytokine or a polynucleotide encoding a further cytokine, wherein the further cytokine may be IL7 or IL21. The T cells genetically modified to express a CAR may be provided to the subject by administering the T cells genetically modified to express a CAR or by generating the T cells genetically modified to express a CAR in the subject. The methods of the disclosure may further comprise administering to the subject an antigen or a variant thereof, or a polynucleotide encoding an antigen or a variant thereof, wherein the T cell genetically modified to express a CAR are targeted to the antigen. In one particularly preferred embodiment, the polynucleotides administered according to the present disclosure are RNA.
PURPOSE: An inhibitor for macrophage autophagy action containing interleukin-10 is provided to induce PI3kinase I activation and to effectively suppress autophagy action. CONSTITUTION: An inhibitor for macrophagy autophagy action contains interleukin-10 as an active ingredient. The interleukin-10 suppresses the autophagy by inducing PI3 kinase I activation using cellular signal transduction. The inhibitor is used for treating and preventing type 1 diabetes and autophagy-activated cancer. A promoter for macrophagy autophgy action contains IL-10 receptor binding inhibitor or PI3kinase I activation inhibitor. The PI3kinase I activation inhibitor is 22-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one.
PROBLEM TO BE SOLVED: To obtain the subject new protein, No-r protein S, exhibiting vasohypotonic activity, blood platelet agglutination inhibitory activity and phylactic activity, and useful as e.g. a vasohypotonic agent, by binding nitrogen monoxide to a protein isolated from the salivary gland of a sucking insect. SOLUTION: This protein is new NO-r protein S which is formed by binding nitrogen monoxide (NO) to r-protein S, a protein isolated from the salivary gland of sucking insects, produced by cloning and composed of a base sequence- amino acid sequence of the formula. This new protein has vasohypotonic activity, blood platelet agglutination inhibitory activity and (bio)phylactic activity, being useful, as a vasohypotonic agent, for treating/preventing hypertension, lung hypertension, myocardial infarction, cerebral infarction, pulmonary infarction, vasospasm following subaracthnoid hemorrhage, etc. This protein is obtained by the following process: the salivary gland of a sucking insect (e.g.  Rhodnius prolixus) is withdrawn, frozen with e.g. liquid nitrogen and ground in a physiological saline solution, and the resultant liquid is centrifuged, the resulting supernatant is fractionated by chromatography and the resulting active fraction is taken, and an NO gas-saturated liquid is then added to the fraction.
Women who inject drugs (WWIDs) are at significantly higher risk of contracting HIV due to both needle sharing and sexual behaviors, yet utilize HIV prevention resources less. Analysis of studies testing pre-exposure prophylaxis (PrEP) has not tested effectiveness in WWIDs and little research exists on their specific barriers to uptake and adherence. The result is a significant group who is highly vulnerable to HIV infection and its negative health consequences, yet is less likely to benefit from PrEP. To address this gap this study will use a rigorous formative evaluation strategy utilizing a unique and innovative marketing evaluation technique. Using perceptual mapping and vector modeling analysis, the investigators will develop 3-D maps to identify specific message strategies to embed into an intervention using targeted PrEP counseling, written materials, and text based messaging and pilot tested for promise of efficacy compared to a general PrEP intervention. The intervention will address psycho-social barriers to PrEP through perceptual mapping but also societal and structural barriers by embedding it in a trusted syringe exchange and distributing medication through its medical clinic. Specific aims of the research are: 1. Assess WWIDs' perceptions of PrEP and potential barriers to use. To accomplish this the investigators will conduct focus groups (n=30) and interviews with syringe exchange staff (n=10) and develop a perceptual mapping survey. 2. Develop a targeted communication intervention based on vector modeling findings, including print materials, PrEP counseling, and text messages, and assess feasibility and acceptability. To accomplish this the investigators will conduct perceptual mapping surveys with HIV- WWIDs (n=100), do vector modeling analysis and create sample messages, concept test messages with WWIDs and staff (n=20), create intervention materials and conduct usability testing (n=20). 3. Pilot test the intervention by integrating into a syringe exchange to assess promise of efficacy. To accomplish this the investigators will conduct a randomized pilot (n=50) and test an "enhanced" intervention using targeted messages with a "basic" intervention that provides general PrEP counseling. To assess promise of efficacy the investigators will compare PrEP adherence (blood test; self report) and differences in PrEP attitudes, self-efficacy, and decisional conflict.
Healthy participants of similar training status as previously tested will be enrolled into the study. The participants will be randomly assigned to either placebo supplementation or to 400 mg ATP per day for 14 days. The supplements will be taken in the morning and the last dose will be taken 30 min prior to testing on the last day. Testing will be performed at baseline and after the 14 days of supplementation. Ten successive sprints will be conducted on the Wingate apparatus as this has been previously demonstrated to decrease muscle excitability. After the sprints, muscle excitability, reaction time, and vertical jump power will be measured. In addition a blood sample will be obtained before and after supplementation and complete blood hematology and chemistry analyses will be performed. It is expected that ATP supplementation may help maintain muscle excitability and power after the successive sprint sessions.
Typically developing infants (5 months old, SD .5 months at entry) were followed longitudinally as a comparison for postural variables. The primary outcome measure is Center of Pressure (COP) data, from which linear and nonlinear variables were extracted. The Gross Motor Function Measure (GMFM) sitting subsection was our clinical outcome measure.
T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy.
A receptor protein specifically recognizing a bacterial DNA having an unmethylated CpG sequence; a gene DNA encoding the same; and model animals useful in studying immune responses of immunocytes to bacterial infectious diseases. A DNA encoding a receptor protein specifically recognizing a bacterial DNA having an unmethylated CpG sequence is screened by the BLAST search method. Next, a number of EST clones highly analogous to various TLRs are screened. By using these clones as probes, a full-length cDNA is isolated from a mouse macrophage cDNA library. After analysing the base sequence of the cDNA and confirming that it is TLR9 having conserved domains such as LRR and TIR domains, a knockout mouse is constructed. Thus it is confirmed that TLR9 is a receptor protein of an oligonucleotide containing the unmethylated CpG sequence of a bacterial DNA.
The invention belongs to the technical field of cellular immunotherapy. Aiming at the problem that the existing CAR-T has limited effect of treating liver fibers, a chimeric receptor of specific targeting LX2, a preparation method of a CAR-T cell preparation and application thereof are provided. The chimeric antigen receptor specifically targeting LX2 comprises an anti-FAP single-chain antibody, a hinge region, a transmembrane domain and a signal transduction domain, wherein the amino acid sequences of a light chain variable region VL and a heavy chain variable region VH are respectively shown as SEQ ID NO. 4 and SEQ ID NO. 5. CAR-T cells expressing the chimeric antigen receptor specifically targeted to LX2 as described herein. The chimeric antigen receptor has good specificity for activating hepatic stellate cell markers FAP, and the CAR-T cells expressing the chimeric antigen receptor specifically targeting LX2 have remarkable killing effect on hepatic fibroblasts and hepatic stellate cells.
OBJECTIVE: The aim of the present study was to examine and quantify whether the association between preterm birth (PTB) and pre-pregnancy body mass index (BMI) is mediated by gestational weight gain (GWG).
METHODS: This is a secondary analysis of a large randomized community non-inferiority trial using a cohort design. The data of 26 101 pregnant women in their first trimester who sought prenatal care and met eligibility criteria were included. The four-way decomposition method was applied to screen for all types of association effects of pre-pregnancy BMI on the risk of PTB. These effects include the total, direct, and various indirect effects including pure mediation via GWG, interactive effects with GWG, and mediated interaction with GWG, all adjusted for potential confounders.
RESULTS: Among the study participants, 24 461 (93.7%) had term deliveries, while 1640 (6.3%) experienced PTB. The results of the study showed that there was a positive association between pre-pregnancy BMI among those with BMI more than 25 kg/m2 and the risk of PTB and this association was negatively mediated and interacted by GWG, which differed quantitatively between those who had inadequate, adequate, or excessive GWG. The total association effect showed that the risk was lowest for those who had underweight pre-pregnancy BMI and adequate GWG (excess relative risk [RR]: 0.06, 95% CI: 0.01-0.11, P value: 0.022) and was highest for those who had obese pre-pregnancy BMI and excessive GWG (excess RR: 0.67, 95% CI: 0.35-1.00, P value <0.001).
CONCLUSION: The findings of the present prospective population-based study demonstrated that pre-pregnancy BMI >25 kg/m2 is directly and positively associated with the risk of preterm birth. The highest risk of preterm birth was observed among individuals with an obese pre-pregnancy BMI who also experienced excessive GWG.
Participants will receive access to the 4-week HMP Foundations module with guided meditation practices removed. The active control will include only the didactic content included in HMP without the guided meditation practices.
This invention concerns a totally natural formulation for treating excessweight or adipose tissue, the process for preparing it and its use. Indeed,obesity is conventionally defined as an excess of fat. The excess of fattytissue often represents several hundred calories. It is obviously the resultof an imbalance in what scientists call the energy balance, too much intakeor too little energy use. It is significant that, considering the energybalance, the excess in caloric intake severely aggravates the latentimbalance, due to a system of slowed energy use. That is why the purpose ofthis invention is to provide a natural active formulation that can, withoutconstraint, naturally reduce the intake ingested and encourage assimilation,transit and elimination mechanisms. The natural formulation according to thisinvention is currently a specific selection. Excess weight is a chronicdisease and it will always be necessary to pay attention to intolerance oreven addiction. The side effects....
Subject will receive a single oral dose of acarbose/metformin FDC (Treatment A, 50 mg acarbose/500 mg metformin) in period 1, followed by a single oral dose of 50mg acarbose and 500mg metformin as loose combination (Treatment B) in period 2. Washout interval between 2 treatment periods was at least 7 days.
Spinal cord infarction is a rare condition, accounting for only a small percentage of strokes. It can be classified into cervical and thoracolumbar infarctions, with various factors contributing to its occurrence. Sildenafil, a phosphodiesterase type 5 inhibitor commonly used for erectile dysfunction, has been associated with cardiovascular side effects, including transient hypotension. In this case report, we present the unusual occurrence of spinal cord infarction in a 65-year-old man who had self-administered high doses of sildenafil without a doctor's prescription. The patient experienced severe radicular pain in the lumbar region and subsequent weakness in the lower limbs. Evaluation revealed an anterior spinal cord infarction in the thoracic region, confirmed by MRI imaging. After excluding other potential causes, it was concluded that the intake of sildenafil likely led to systemic hypotension, resulting in spinal cord infarction. This case highlights the importance of considering sildenafil as a possible contributor to spinal cord infarction, particularly when used at high doses. Further studies are needed to better understand the relationship between sildenafil and vascular complications, including spinal cord infarction.
The Intensive mobilization intervention will include the standard care plus at least two additional sessions each day of at least 20 minutes each session focused on task specific sitting, standing and walking activities. The intervention will be schedule to start at 24 hours from symptoms onset and will last 14 days or until the patient is discharged.
The present invention provides a method for counteracting preeclampsia, eclampsia of pregnancy and preterm labor in a pregnant female mammal treated by administering thereto calcitonin gene-related peptide (CGRP) or its analogues including CGRP/adrenomedullin or their peptide or receptor-based analogues, or in combination with a progestin, and with or without a nitric oxide substrate, or a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI2-mimetic, a thromboxane (TXA2) inhibitor, a compound possessing TXA2-agonistic, and TXA2-inhibiting properties, a compound possessing TXA2-antagonistic and PGI2-mimetic activities, and a TXA2 antagonist. CGRP, progesterone and some of the nitric oxide substrate and donor compounds are naturally occurring compounds. As such these agents do not have the same toxicity and allergy problems as the foreign substances that are currently used for similar purposes. During pregnancy uterine blood vessels and the uterine muscles are particularly sensitive to CGRP as well as nitric oxide. Therefore, one could administer a very small quantities of these drugs (i.e., intravenously, subcutaneous, or Implants), the effects are then seen mainly in the uterine muscle and blood vessels, namely increase the blood supply to the uteroplacental unit (hence nutrients and oxygen supply to the fetus through the improved placental circulation), and uterine muscular relaxation thereby ameliorate the signs and symptoms of preeclampsia, and eclampsia, and prevent preterm labor. At these dosages, virtually no systemic effects are induced, making CGRP (which is an endogenous natural product present in human body) extremely safe and effective.
Inducer (I) of mast cell death, contains a fusion protein comprising a protein transduction domain (PTD) and microphthalmia-associated transcription factor (MITF) variant, as active ingredient. An independent claim is also included for a fusion protein (II) comprising His-tag, PTD and MITF variant, where the MITF variant is mi variant, wh variant or bHLH-Zip (basic-helix-loop-helix/leucine zipper) fragment of MITF, and PTD is a TAT peptide-derivative. ACTIVITY : Cytostatic MECHANISM OF ACTION : Inducer of mast cell death (claimed); Inhibitor of mast cell differentiation. Fibroblasts and normal mast cells were cocultivated under conditions such that the mast cell continued to survive for a long period of time. To the culture solution, the fusion protein containing mi variant and wh variant was added. Survival of mast cells was found to be inhibited and after two weeks the cells became extinct. The reduction in the number of mast cells was confirmed by the reduction in histamine amount and reduction in chymase activity. This result suggested that the fusion protein inhibits mast cell growth and induces apoptosis (cell death) of mast cells.